Study of drug-eluting stent Recent.docVIP

 PAGE \* MERGEFORMAT 21 Study of drug-eluting stent Recent [Abstract] since the stent has been used in the human body, is very high (10% to 50%) of in-stent restenosis (In-stent tenosis rate, ISR) rate, has been the main factor impeding their development. Drug-eluting stent greatly reduced the appearance of the incidence of ISR. This paper studies of drug-eluting stent progress are outlined below. [Keywords:] drug-eluting stent, intervention, stent restenosis, coronary heart disease Coronary artery stent implantation is effective treatment of a kind of an important means exactly. But the ISR high limit the development of stent implantation. In September 2001 European Society of Cardiology held in Stockholm, Sweden The annual conference of the RAVEL results: Compared with ordinary stents, sirolimus-eluting stent group, 7 months restenosis rate was zero. In the same year in December, drug-eluting stent (DES is listed as the year the American Heart Diseases Association, the top ten research advances. DES-coated stent material used as a carrier, carrying a certain concentration of a drug to prevent the role of intimal hyperplasia, and make slow, steady release, to the purpose of preventing restenosis. 1 DES Overview ISR support PCI after the mechanism is the process of stent implantation stent (or series of reactions after vascular balloon injury caused, including four kinds of reactions: the formation of thrombus, inflammatory cells, smooth muscle cell migration and proliferation , vascular recoil. DES plaque with the current erosion of surgery, radiation therapy of coronary artery ISR’s methods, with positioning accuracy, high drug concentrations within the target tissue, distribution, role in a long time, and other systemic side effects characteristics. It is based on prevention, taking into account treatment, with a very high price. DES stent surface by a carrier-specific controlled release some of the anti-proliferative drugs or genes, cells, et